Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 12, 2019
OncoCyte Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early ...
February 11, 2019
Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuros’s Advanced Submicron Surface Technology
SCHLIEREN (ZURICH), Switzerland, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private ...
February 11, 2019
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of ...
February 11, 2019
TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing metabolic-based cancer therapies, today reported its financial and ...
February 11, 2019
Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina
VANCOUVER , Feb. 11, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve technologies ...
February 11, 2019
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a Fortress Biotech (FBIO) company, today announced the completion of the first ...
February 11, 2019
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
REDWOOD CITY, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell ...
February 11, 2019
Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced ...
February 11, 2019
AIT Therapeutics Announces Appointment of Robert F. Carey to Board of Directors
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
February 11, 2019
CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors
MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
February 11, 2019
Kiadis Pharma to participate in a panel at Innovation for Health 2019
Amsterdam, The Netherlands, February 11, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today ...
February 11, 2019
Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that Professor Gareth Thomas ...
February 7, 2019
Basilea announces change in the Management Committee - Adesh Kaul appointed CFO
Basel, February 7, 2019 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that the Board of Directors has appointed Adesh Kaul, currently Chief Corporate Development Officer ...
February 7, 2019
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
LAUSANNE, Switzerland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, ...
February 7, 2019
InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19
TEL AVIV, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
February 7, 2019
Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the ...
February 7, 2019
OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases
NANTES, France and PARIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced that Servier, an independent international pharmaceutical company, ...
February 7, 2019
Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering
ISFIYA, Israel, Feb. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first ...
February 7, 2019
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed ...
February 7, 2019
Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced financial results for its fiscal 2019 first quarter ended December 31, 2018. The company is hosting a ...
Page 14 of 138